“In short, we are pleased with the biological development during the quarter. This lays the foundation for increased volume and positive cost development in the second half of the year. Financially Q2 2025 was weak, as expected, due to poor price achievement in the quarter,” says Frode Arntsen, CEO of SalMar ASA.
SalMar - Strong biological development throughout the quarter
Seeking Alpha / 18 hours ago 6 Views
Comments